Healthcare Services

Malignant Mesothelioma Market Insights Covering Trends and Opportunities

April 23, 2026April 26, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Malignant Mesothelioma Market From 2026 To 2030?

The malignant mesothelioma market has experienced robust expansion in recent years. It is anticipated to increase from $2.61 billion in 2025 to $2.77 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. The growth observed historically can be attributed to previous asbestos exposure in construction and manufacturing, the extended latency period of the disease, restricted early treatment options, growing awareness of occupational health, and progressive enhancements in diagnostic imaging.

The malignant mesothelioma market size is anticipated to experience substantial growth in the coming years. It is projected to expand to $3.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.3%. This expansion during the forecast period is attributable to breakthroughs in immunotherapy and targeted drugs, increased investment in rare cancer research, a rising number of clinical trials, enhanced diagnostic technologies, and growing healthcare spending on oncology. Significant trends expected in the forecast period include the increasing adoption of immunotherapy and targeted therapy, a greater emphasis on multimodal treatment approaches, an escalating demand for early and accurate diagnosis, the expansion of specialized mesothelioma treatment centers, and higher participation in clinical trials for rare cancers.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22046&type=smp

What Key Factors Are Shaping The Malignant Mesothelioma Market Landscape?

Ongoing expansion in clinical research and development endeavors is projected to stimulate the growth of the malignant mesothelioma market moving forward. These R&D efforts encompass conducting scientific investigations and trials aimed at inventing new pharmaceuticals, therapies, and medical devices, which includes assessing their safety, efficacy, and potential adverse reactions through structured clinical trials. The heightened focus on clinical R&D is attributable to the escalating need for innovative and enhanced treatments, particularly with the increasing prevalence of chronic diseases and intricate conditions. Such research and development initiatives propel the malignant mesothelioma market by accelerating progress in diagnostics, treatments, and precise therapies, thereby fostering inventive strategies to improve early detection, boost survival rates, and devise more effective, less invasive therapeutic alternatives. For instance, in January 2025, as reported by Anadolu Agency, a state-run news agency based in Turkey, clinical trials constitute nearly 40% of the U.S. pharmaceutical research budget, amounting to approximately $7 billion annually. Consequently, the escalating research and development activities are driving the expansion of the malignant mesothelioma market.

What Segment Categories Shape The Malignant Mesothelioma Market Segment Landscape?

The malignant mesothelioma market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Radiation Therapy, Surgery, Immunotherapy, Targeted Therapy

2) By Route Of Administration: Oral, Intravenous, Injectable

3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

4) By End-User: Hospitals, Oncology Clinics

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Combination Therapy

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy

3) By Surgery: Pleurectomy Or Decortication (P/D), Extrapleural Pneumonectomy (EPP), Cytoreductive Surgery, Palliative Surgery

4) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Tumor Vaccines, Adoptive Cell Therapy

5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Angiogenesis Inhibitors, Mesothelin-Targeted Agents, Gene Therapy-Based Approaches

What Market Trends Are Affecting The Malignant Mesothelioma Market?

Key companies operating in the malignant mesothelioma market are concentrating on developing advanced treatment options, such as monoclonal antibody therapies, with the goal of inhibiting tumor growth and improving treatment precision. Monoclonal antibodies are laboratory-produced proteins designed to mimic the immune system’s inherent ability to detect and target specific antigens, like those found on cancer cells. For instance, in November 2023, Ono Pharmaceutical Co. Ltd., a pharmaceutical company located in Japan, received supplemental approval in Japan for the expanded use of Opdivo (nivolumab), a human anti-human PD-1 monoclonal antibody for treating malignant mesothelioma (excluding malignant pleural mesothelioma). This approval establishes Opdivo as a new therapeutic choice for this condition, for which no standard treatments had previously been established. Opdivo was also designated an orphan drug for this indication, emphasizing its potential to address a significant medical need.

Who Are The Companies Operating Across The Malignant Mesothelioma Market Value Chain?

Major companies operating in the malignant mesothelioma market are AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Gilead Sciences Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Bayer AG, Eisai Co. Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co. Ltd., PharmaMar S.A.

Get The Full Malignant Mesothelioma Market Report:

https://www.thebusinessresearchcompany.com/report/malignant-mesothelioma-global-market-report

Which Region Accounts For The Largest Portion Of The Malignant Mesothelioma Market?

North America was the largest region in the malignant mesothelioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Malignant Mesothelioma Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/malignant-mesothelioma-global-market-report

Browse Through More Reports Similar to the Global Malignant Mesothelioma Market 2026, By The Business Research Company

Melanoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/melanoma-therapeutics-global-market-report

Metastatic Melanoma Therapeutics Market Report

https://www.thebusinessresearchcompany.com/report/metastatic-melanoma-therapeutics-global-market-report

Melanoma Drugs Market Report

https://www.thebusinessresearchcompany.com/report/melanoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795